FTSE MIB
33.746,66 -549,65 (-1,60%) Dow Jones
37.903,29 +87,37 (+0,23%) Nasdaq
15.605,48 -52,34 (-0,33%) Nikkei 225
38.274,05 -131,61 (-0,34%) Petrolio
79,16 -2,77 (-3,38%) Bitcoin EUR
53.547,06 -2.313,84 (-4,14%)
Regeneron Pharmaceuticals, Inc. (0R2M.L)
| Chiusura precedente | 890,19 |
| Aperto | 894,99 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 887,97 - 901,12 |
| Intervallo di 52 settimane | 689,00 - 998,57 |
| Volume | |
| Media Volume | 1.962 |
| Capitalizzazione | 999,293M |
| Beta (5 anni mensile) | 0,14 |
| Rapporto PE (ttm) | 0,13 |
| EPS (ttm) | 70,31 |
| Prossima data utili | 02 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireRegeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
Event-free survival of investigational use of Libtayo® (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be featured in oral presentation First data for the investigational combination of Libtayo and ubamatamab (MUC16xCD3) in recurrent ovarian cancer also to be presented Additional presentations on outcomes of Libtayo-based therapy in advanced non-small cell lung cancer, including PD-L1 expression and histology specific subgroups TARRYTOWN, N.Y., Oct. 15,
- GlobeNewswire
EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA
First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two yearsTARRYTOWN, N.Y., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive two-year (96 weeks) results from the pivotal PULSAR trial investigating EYLEA® HD (aflibercept) Injection 8 mg with 12- and 16-week dosing regimens, compared to EYLEA® (aflibercept) Injection, in patients with wet
GlobeNewswireRegeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research collabo
